利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.074 秒)

    Diagnosis of sepsis or SIRS using biomarker profiles
    2.
    发明授权
    Diagnosis of sepsis or SIRS using biomarker profiles 有权
    使用生物标志物图谱诊断败血症或SIRS

    公开(公告)号：US07645573B2

    公开(公告)日：2010-01-12

    申请号：US10704666

    申请日：2003-11-12

    申请人： Richard M. Ivey ,  Thomas M. Gentle, Jr. ,  Richard L. Moore ,  Michael L. Towns ,  Nicholas Bachur, Jr. ,  Robert W. Rosenstein ,  Paul E. Goldenbaum ,  Song Shi ,  Donald Copertino ,  James Garrett ,  Gregory Tice

    发明人： Richard M. Ivey ,  Thomas M. Gentle, Jr. ,  Richard L. Moore ,  Michael L. Towns ,  Nicholas Bachur, Jr. ,  Robert W. Rosenstein ,  Paul E. Goldenbaum ,  Song Shi ,  Donald Copertino ,  James Garrett ,  Gregory Tice

    IPC分类号： C12Q1/68 ,  C12P19/34

    CPC分类号： C12Q1/6883 ,  C12Q1/6837 ,  C12Q1/686 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2800/26

    摘要： The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished using a molecular diagnostics approach, involving comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population who develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated at the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.

    摘要翻译： 败血症的早期预测或诊断有利地允许在疾病快速进展到初始阶段之前的临床干预到更严重的阶段，例如与高死亡率相关的更严重的败血症或败血性休克。 使用分子诊断方法实现早期预测或诊断，包括将个体的生物标志物表达谱与从一个或多个对照或参考群体获得的概况进行比较，其可包括发生败血症的群体。 识别个体生物标志物特征的特征是脓毒症发作的特征，允许临床医生在单个时间点从个体分离的体液诊断败血症的发作。 因此，避免在一段时间内监测患者的必要性，有利地允许在严重症状发作之前进行临床干预。 此外，因为生物标志物的表达被测定其特征，所以特定生物标志物的鉴定是不必要的。 个体的生物标记谱与适当参考群的生物标志物概况的比较同样可以用于诊断个体中的SIRS。

    Diagnosis of sepsis or SIRS using biomarker profiles
    4.
    发明申请
    Diagnosis of sepsis or SIRS using biomarker profiles 审中-公开
    使用生物标志物图谱诊断败血症或SIRS

    公开(公告)号：US20080138832A1

    公开(公告)日：2008-06-12

    申请号：US11904282

    申请日：2007-09-25

    申请人： Richard M. Ivey ,  Thomas M. Gentle ,  Richard L. Moore ,  Michael L. Towns ,  Nicholas Bachur ,  Robert W. Rosenstein ,  James G. Nadeau ,  Paul E. Goldenbaum ,  Song Shi ,  Donald Copertino ,  James Garrett ,  Gregory Tice

    发明人： Richard M. Ivey ,  Thomas M. Gentle ,  Richard L. Moore ,  Michael L. Towns ,  Nicholas Bachur ,  Robert W. Rosenstein ,  James G. Nadeau ,  Paul E. Goldenbaum ,  Song Shi ,  Donald Copertino ,  James Garrett ,  Gregory Tice

    IPC分类号： G01N33/53 ,  C12Q1/02 ,  G01N33/00

    CPC分类号： G01N33/6803 ,  C12Q1/6837 ,  C12Q1/686 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N2800/26

    摘要： The early prediction or diagnosis of sepsis advantageously allows for clinical intervention before the disease rapidly progresses beyond initial stages to the more severe stages, such as severe sepsis or septic shock, which are associated with high mortality. Early prediction or diagnosis is accomplished by comparing an individual's profile of biomarker expression to profiles obtained from one or more control, or reference, populations, which may include a population that develops sepsis. Recognition of features in the individual's biomarker profile that are characteristic of the onset of sepsis allows a clinician to diagnose the onset of sepsis from a bodily fluid isolated from the individual at a single point in time. The necessity of monitoring the patient over a period of time is, therefore, avoided, advantageously allowing clinical intervention before the onset of serious symptoms of sepsis. Further, because the biomarker expression is assayed for its profile, identification of the particular biomarkers is unnecessary. The comparison of an individual's biomarker profile to biomarker profiles of appropriate reference populations likewise can be used to diagnose SIRS in the individual.

    摘要翻译： 败血症的早期预测或诊断有利地允许在疾病快速进展到初始阶段之前的临床干预到更严重的阶段，例如与高死亡率相关的更严重的败血症或败血性休克。 通过将个体的生物标志物表达谱与从一个或多个对照或参考群体获得的概况进行比较来实现早期预测或诊断，其可包括发生败血症的群体。 识别个体生物标志物特征的特征是脓毒症发作的特征允许临床医生在单个时间点诊断从个体分离的体液的败血症发作。 因此，避免在一段时间内监测患者的必要性，有利地允许在脓毒症严重症状发作之前进行临床干预。 此外，因为生物标志物的表达被测定其特征，所以特定生物标志物的鉴定是不必要的。 个体的生物标记谱与适当参考群的生物标志物概况的比较同样可以用于诊断个体中的SIRS。

    Method for reducing blood carbon dioxide background in bacterial media by the addition of micelles of saponin and a phospholipid
    6.
    发明授权
    Method for reducing blood carbon dioxide background in bacterial media by the addition of micelles of saponin and a phospholipid 失效
    通过加入皂角苷和磷脂的胶束来减少细菌培养基中血二氧化碳背景的方法

    公开(公告)号：US4994378A

    公开(公告)日：1991-02-19

    申请号：US404475

    申请日：1989-09-08

    申请人： Dolores M. Berger ,  Paul E. Goldenbaum ,  Gregory Tice

    发明人： Dolores M. Berger ,  Paul E. Goldenbaum ,  Gregory Tice

    IPC分类号： C12Q1/04

    CPC分类号： C12Q1/04

    摘要： A non-ionic lytic agent, preferably saponin for reducing the background carbon dioxide produced by blood cell metabolism is used in the testing of cultures for the presence of microorganisms. The hemolytic agent saponin is combined with a phospholipid, preferably L-.alpha.-Lecithin (phosphatidylcholine), to form mixed micelles which protect saponin from the effects of heat sterilization and high blood cholesterol levels, thus maintaining the lytic activity of saponin. The phospholipid/saponin mixed micelles are added to non-radiometric culture media vials such as Bactec.RTM. NR6A, NR7A and NR8A. The media vials are used in the Bactec.RTM. NR-660 and NR-730 instruments. However, the present invention may also be used in radiometric media such as Bactec.RTM. culture vials 6, 7 and 8 for reducing background carbon dioxide levels detected in C.sup.14 radiometric instruments such as the Bactec.RTM.-460, or in other instruments designed to detect bacteria in the presence of mammalian cells by monitoring the increase in CO.sub.2 produced by the metabolizing bacteria.

    摘要翻译： 用于减少血液细胞代谢产生的背景二氧化碳的非离子溶解剂，优选皂苷用于微生物存在的培养物的测试中。 溶血剂皂苷与磷脂，优选L-α-卵磷脂（磷脂酰胆碱）组合形成混合的胶束，其保护皂苷免受热灭菌和高血胆固醇水平的影响，从而保持皂角苷的溶解活性。 将磷脂/皂角苷混合胶束加入非辐射培养基小瓶如Bactec TM NR6A，NR7A和NR8A。 介质小瓶用于Bactec TM NR-660和NR-730仪器。 然而，本发明也可以用于辐射介质如Bactec TM培养瓶6,7和8中，用于降低C14辐射仪器如Bactec TM -460中检测到的背景二氧化碳水平，或用于其他设计用于检测细菌的仪器 在哺乳动物细胞的存在下，通过监测由代谢细菌产生的CO 2的增加。

    Method for differentiating microorganisms in a sample
    7.
    发明授权
    Method for differentiating microorganisms in a sample 有权
    分析样品中微生物的方法

    公开(公告)号：US6130057A

    公开(公告)日：2000-10-10

    申请号：US407638

    申请日：1999-09-28

    申请人： C. Michael Gosnell ,  Carrie A. Hughes ,  Paul E. Goldenbaum

    发明人： C. Michael Gosnell ,  Carrie A. Hughes ,  Paul E. Goldenbaum

    IPC分类号： C12N1/00 ,  C12Q1/04 ,  C12Q1/18 ,  C12Q1/02

    CPC分类号： C12Q1/045 ,  Y10S435/968

    摘要： Culture media for microorganisms containing blood or hemin, particularly Trypticase Soy Agar with blood, and chocolate agar, are combined with known chromogenic substrates to produce chromogenic media. Methods for preparing these chromogenic media include adding chromogenic substrates to the surface of previously prepared media, or incorporating the chromogenic substrate into the media as it is prepared. Methods for distinguishing microorganisms in a sample using these culture media are also described.

    摘要翻译： 用于含有血液或血红素的微生物的培养基，特别是具有血液的胰蛋白酶大豆琼脂和巧克力琼脂与已知的显色底物组合以产生显色培养基。 制备这些显色培养基的方法包括将生色底物添加到先前制备的培养基的表面，或者在制备时将生色底物掺入培养基中。 还描述了使用这些培养基来区分样品中微生物的方法。